93results about How to "Increase apoptosis rate" patented technology

The invention relates to a preparation method of coix seed polysaccharide. The preparation method comprises the following steps of: crushing and screening coix seeds first, and carrying out degreasing, water bath extraction, centrifugation, enzymolysis, concentration, alcohol precipitation and vacuum freeze drying and precipitation to obtain crude coix seed polysaccharide; and dissolving the prepared crude coix seed polysaccharide to obtain a crude coix seed polysaccharide solution, carrying out deproteinization, decoloration, dialysis and ion exchange chromatography on the crude coix seed polysaccharide solution to obtain purified coix seed polysaccharide, and then carrying out vacuum freeze drying to obtain white powder, namely the coix seed polysaccharide. According to the preparation method disclosed by the invention, the crude coix seed polysaccharide is extracted by using a water extraction and alcohol precipitation method, the crude coix seed polysaccharide is subjected to deproteinization, decoloration, dialysis and ion exchange chromatography to obtain the purified coix seed polysaccharide, and then, the purified coix seed polysaccharide is subjected to vacuum freeze drying to obtain the white powder, namely the coix seed polysaccharide; and therefore, the preparation method is simple and the coix seed polysaccharide is high in yield.

A method of treating a tumor, comprising creating an elevated concentration of free radicals in said tumor and creating a magnetic field that traverses said tumor and that inhibits the recombination of said free radicals in said tumor, thereby increasing the rate of apoptosis of cancerous cells. A magnetic field of 0.1 mTesla to 10 mTesla is generally used for this purpose.

The invention discloses a cell electrochemical sensor for analyzing joint toxicity of fungaltoxin, belonging to the fields of analysis and detection of food quality. According to the cell electrochemical sensor, the sensitivity of the sensor is increased by virtue of electroplating gold nanoparticles, an in-vivo physiological living environment of cells is simulated by virtue of laminin, and a three-dimensional model is constructed by virtue of rat tail collagens so as to relatively truly reappear cell morphology; and the constructed cell electrochemical sensor can rapidly and sensitively respond to the influences caused by the fungaltoxin to human hepatoma carcinoma cells, equipment is convenient and rapid and low in production cost, and by combining with an electrochemical resistance value and a joint index method, the type and degree of a joint action of the fungaltoxin can be rapidly judged. The constructed portable cell electrochemical sensor is successfully applied to the toxicity analysis of the fungaltoxin in foods and has good application prospects in the analysis of the joint toxicity of the fungaltoxin.

The invention belongs to the medical and biotechnical fields and in particular relates to application of a mesenchymal stem cell in preparation of a medicine used for treating M5 type leukaemia. The mesenchymal stem cell provided by the invention is obtained by stimulating specific inflammatory factors TNF-alpha and IFN-gamma; the capability of the mesenchymal stem cell for inducing tumor cell apoptosis is realized by a tumor necrosis factor-related apoptosis inducing ligand TRAIL; and the mesenchymal stem cell is in vitro. By virtue of stimulation on TNF-alpha and IFN-gamma, the TRAIL expression capability of the mesenchymal stem cell is obviously improved, and anti-tumour capability is obviously enhanced; compared with chemical therapy, toxic and side effects in mesenchymal stem cell transplantation are lower; due to low immunogenicity of the mesenchymal stem cell, morbidity of graft versus host disease is also greatly reduced, clinical requirement is met, and a new thought is provided for stem cell transplantation therapy. The mesenchymal stem cell can be applied to preparation of the medicine used for treating the M5 type leukaemia.

The invention relates to antitumor drugs and discloses anti-glioma drugs based on Venenum Bufonis extract and a preparation method thereof, the drugs being a bufotalin submicron emulsion and a bufotalin nanoparticle preparation, wherein the bufotalin submicron emulsion comprises Venenum Bufonis extract, medium chain triglyceride, a lecithin, poloxamer 188, glycerol, sodium oleate and injection water; the bufotalin nanoparticle preparation comprises Venenum Bufonis extract, glycerol monostearate, medium-chain fatty acid glyceride, oleic acid, a lecithin, poloxamer 188, sodium deoxycholate and injection water. Both the two preparations can combine with endothelial cells in cerebral blood capillaries, enabling the drugs to be transmitted into the brain through membranes or by means of adsorption, medication, endocytosis and transferring, cerebral targeting of the drugs is improved, and further increase of bufotalin in the brain is facilitated, and glioma resistance is achieved by inducing apoptosis and excessive autophagy of cells.

The invention relates to the technical field of medicaments, and discloses a transcatheter arterial chemoembolization embolism agent containing an autophagy inhibitor for treating liver cancer. The embolism agent consists of a chemotherapy medicament, the autophagy inhibitor and iodized oil, wherein the chemotherapy medicament is cis-platinum; the iodized oil is liquid iodized oil; and the autophagy inhibitor is selected from bafilomycin A1 or chloroquine. The bafilomycin A1 or the chloroquine can be used as a sensitizer of the chemotherapy medicament, and can increase the sensitivity of liver cancer cells to the chemotherapy medicament in a hypoxic ischemic microenvironment after embolism and enhance the anti-cancer effect of the chemotherapy medicament. Animal experiments show that the embolism agent can achieve good curative effect for treating middle and late primary liver cancers, obviously increase the apoptosis rate and the necrosis rate of tumor cells and remarkably reduce tumors so as to improve the curative effect of transcatheter arterial chemoembolization. The invention provides the embolism agent with good curative effect and low injury for the transcatheter arterial chemoembolization.

Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

The present invention provides a method for treatment of leukemia comprising administration of arginase to a subject in need thereof. In one embodiment, the leukemia is lymphocytic or myeloid. In another embodiment, the leukemia is arsenic resistant. In a further embodiment, the arginase is pegylated recombinant human arginase. In another embodiment, the arginase can be administrated in combination with a second therapeutic agent such as Doxorubicin in the treatment of leukemia.

The invention provides a pulsed magnet field generator based on coil spherical focusing and IGBT single transistor parallel connection. The pulsed magnet field generator comprises a power supply system, a pulse current forming system, five coil spherical optimization focusing devices, a signal transformation system and a synchronized trigger module, and the switching power supply of the power supply system carry out voltage reduction on an alternating current power supply to form direct currents, is connected with the pulse current forming system, the signal transformation system and the synchronized trigger module and supplies power. The output ends of pulse generating modules M1-M5are connected with current carrying coils C1-C5 in the five coil spherical optimization focusing devices respectively. The electrical-optical converter J2 of the signal transformation system is respectively connected with the control ends of the pulse generating modules M1-M5. The output end of the synchronized trigger module is respectively connected with the electrical-optical converter J1 and the electrical-optical converter J2 of the signal transformation system. The pulsed magnet field generator is high in integration level, longer in service life and higher in work efficiency, the circuit size is greatly reduced, and the loss of the whole circuit is lowered.

The present invention discloses a model for evaluating an HR defect and its application. Based on a tumor individualized chemotherapy strategy, the method evaluates whether HR in gallbladder cancer cells is defective by using an existing HR-related indicator, and inhibits autophagy and PARP treatment according to normal HR or defective HR, improves the anti-tumor efficacy of a chemotherapy regimenFAM, and avoids the occurrence of resistance after multiple rounds of highly toxic medication for the patient. A multi-molecular marker used for detecting gallbladder cancer cells contains only 15 genes, is liable to clinical trials, reduces the cost of detection, and is not affected by the batch effect of experiments or the difference in the detection platforms, does not require data standardization between multiple samples before use, and is easy to use.

The invention discloses application of a CTNNB1 gene in porcine ovarian granulosa cells, and belongs to the technical field of cell engineering and gene engineering. According to the invention, the relative expression quantity of CTNNB1 mRNA in ovarian tissues, follicles with different sizes and granulosa cells of pigs in different periods, and the proliferation and apoptosis of the granulosa cells after overexpression and inhibition of CTNNB1 and the secretion of steroid hormones are detected. Results show that the CTNNB1 gene participates in promoting the proliferation of granulosa cells andthe secretion of estradiol and inhibiting the apoptosis of granulosa cells and the secretion of testosterone and progesterone, which indicates that the CTNNB1 gene participates in the development andmaturation of ovarian follicles of sows. Materials are accumulated for molecular mechanism research in the sow ovarian follicle development process.

The invention belongs to the technical field of biology, and particularly relates to an in-vitro cytokine storm model and a construction method and application thereof. The construction system of the in-vitro cytokine storm model contains a TNF-alpha factor, an IL-1[beta] factor, an IL-6 factor and vascular endothelial cells. The in-vitro cytokine storm model is formed by the body. According to the in-vitro cytokine storm model construction method, vascular endothelial cells, TNF-alpha factors, IL-1[beta] factors and IL-6 factors are incubated together. The invention discloses application of an in-vitro cytokine storm model in screening of anti-cytokine release syndrome drugs. The invention relates to an application of an in-vitro cytokine storm model in preparing and screening anti-cytokine release syndrome drugs. The in-vitro cytokine storm model disclosed by the invention is obtained by jointly treating vascular endothelial cells through three factors, namely TNF-alpha, IL-1[beta] and IL-6, the in-vitro cytokine storm model with high cell apoptosis rate and obviously reduced cell activity can be prepared, and a better basis is provided for research on inflammatory response related to multiple factors.